B. Metzler Seel. Sohn & Co. Ag Arrowhead Pharmaceuticals, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 18,705 shares of ARWR stock, worth $393,740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,705
Previous 18,705
-0.0%
Holding current value
$393,740
Previous $486,000
25.51%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ARWR
# of Institutions
295Shares Held
91.1MCall Options Held
155KPut Options Held
426K-
Black Rock Inc. New York, NY15.7MShares$330 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$257 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$187 Million2.59% of portfolio
-
State Street Corp Boston, MA6.35MShares$134 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.89MShares$103 Million1.49% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.23B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...